180 related articles for article (PubMed ID: 14871978)
1. Ubiquitous aberrant RASSF1A promoter methylation in childhood neoplasia.
Wong IH; Chan J; Wong J; Tam PK
Clin Cancer Res; 2004 Feb; 10(3):994-1002. PubMed ID: 14871978
[TBL] [Abstract][Full Text] [Related]
2. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines.
Harada K; Toyooka S; Maitra A; Maruyama R; Toyooka KO; Timmons CF; Tomlinson GE; Mastrangelo D; Hay RJ; Minna JD; Gazdar AF
Oncogene; 2002 Jun; 21(27):4345-9. PubMed ID: 12082624
[TBL] [Abstract][Full Text] [Related]
3. Re-expression of RASSF1A by 5-Aza-CdR induced demethylation of the promoter region in human biliary tract carcinoma cells.
Zuo S; Chen Y; Xu L; Tang Q; Zou S
J Huazhong Univ Sci Technolog Med Sci; 2007 Jun; 27(3):281-4. PubMed ID: 17641842
[TBL] [Abstract][Full Text] [Related]
4. Intensive hypermethylation of the CpG island of Ras association domain family 1A in hepatitis B virus-associated hepatocellular carcinomas.
Zhong S; Yeo W; Tang MW; Wong N; Lai PB; Johnson PJ
Clin Cancer Res; 2003 Aug; 9(9):3376-82. PubMed ID: 12960125
[TBL] [Abstract][Full Text] [Related]
5. The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix.
Cohen Y; Singer G; Lavie O; Dong SM; Beller U; Sidransky D
Clin Cancer Res; 2003 Aug; 9(8):2981-4. PubMed ID: 12912945
[TBL] [Abstract][Full Text] [Related]
6. Frequent epigenetic inactivation of the RASSF1A tumor suppressor gene in Hodgkin's lymphoma.
Murray PG; Qiu GH; Fu L; Waites ER; Srivastava G; Heys D; Agathanggelou A; Latif F; Grundy RG; Mann JR; Starczynski J; Crocker J; Parkes SE; Ambinder RF; Young LS; Tao Q
Oncogene; 2004 Feb; 23(6):1326-31. PubMed ID: 14961078
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic inactivation of RASSF1A in head and neck cancer.
Dong SM; Sun DI; Benoit NE; Kuzmin I; Lerman MI; Sidransky D
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3635-40. PubMed ID: 14506151
[TBL] [Abstract][Full Text] [Related]
8. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
[TBL] [Abstract][Full Text] [Related]
9. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma.
Zhang YJ; Ahsan H; Chen Y; Lunn RM; Wang LY; Chen SY; Lee PH; Chen CJ; Santella RM
Mol Carcinog; 2002 Oct; 35(2):85-92. PubMed ID: 12325038
[TBL] [Abstract][Full Text] [Related]
10. Promoter hypermethylation of DNA damage response genes in hepatocellular carcinoma.
Li Z; Zhang H; Yang J; Hao T; Li S
Cell Biol Int; 2012 May; 36(5):427-32. PubMed ID: 21864295
[TBL] [Abstract][Full Text] [Related]
11. Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma.
Yang Q; Zage P; Kagan D; Tian Y; Seshadri R; Salwen HR; Liu S; Chlenski A; Cohn SL
Clin Cancer Res; 2004 Dec; 10(24):8493-500. PubMed ID: 15623630
[TBL] [Abstract][Full Text] [Related]
12. Critical role of deltaDNMT3B4/2 in regulating RASSF1A promoter-specific DNA methylation in non-small cell lung cancer.
Wang SH; Liu NH; Wang J; Bai H; Mao L
Chin Med J (Engl); 2008 Sep; 121(17):1712-21. PubMed ID: 19024105
[TBL] [Abstract][Full Text] [Related]
13. Aberrant promoter hypermethylation and silencing of the critical 3p21 tumour suppressor gene, RASSF1A, in Chinese oesophageal squamous cell carcinoma.
Wong ML; Tao Q; Fu L; Wong KY; Qiu GH; Law FB; Tin PC; Cheung WL; Lee PY; Tang JC; Tsao GS; Lam KY; Law S; Wong J; Srivastava G
Int J Oncol; 2006 Mar; 28(3):767-73. PubMed ID: 16465383
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC).
Niklinska W; Naumnik W; Sulewska A; Kozłowski M; Pankiewicz W; Milewski R
Folia Histochem Cytobiol; 2009; 47(2):275-80. PubMed ID: 19926549
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of RASSF1A tumor suppressor gene by aberrant promoter hypermethylation in human pituitary adenomas.
Qian ZR; Sano T; Yoshimoto K; Yamada S; Ishizuka A; Mizusawa N; Horiguchi H; Hirokawa M; Asa SL
Lab Invest; 2005 Apr; 85(4):464-73. PubMed ID: 15711568
[TBL] [Abstract][Full Text] [Related]
16. SLIT2 promoter methylation analysis in neuroblastoma, Wilms' tumour and renal cell carcinoma.
Astuti D; Da Silva NF; Dallol A; Gentle D; Martinsson T; Kogner P; Grundy R; Kishida T; Yao M; Latif F; Maher ER
Br J Cancer; 2004 Jan; 90(2):515-21. PubMed ID: 14735202
[TBL] [Abstract][Full Text] [Related]
17. Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma.
Byun DS; Lee MG; Chae KS; Ryu BG; Chi SG
Cancer Res; 2001 Oct; 61(19):7034-8. PubMed ID: 11585730
[TBL] [Abstract][Full Text] [Related]
18. Promoter hypermethylation profile of RASSF1A, FHIT, and sFRP1 in intracranial primitive neuroectodermal tumors.
Chang Q; Pang JC; Li KK; Poon WS; Zhou L; Ng HK
Hum Pathol; 2005 Dec; 36(12):1265-72. PubMed ID: 16311119
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic reactivation of RASSF1A by phenethyl isothiocyanate (PEITC) and promotion of apoptosis in LNCaP cells.
Boyanapalli SS; Li W; Fuentes F; Guo Y; Ramirez CN; Gonzalez XP; Pung D; Kong AN
Pharmacol Res; 2016 Dec; 114():175-184. PubMed ID: 27818231
[TBL] [Abstract][Full Text] [Related]
20. [Different hypermethylation status of RASSF1A in medulloblastoma and supratentorial primitive neuroectodermal tumor].
Chang Q; Ng HK
Zhonghua Bing Li Xue Za Zhi; 2007 Jan; 36(1):24-8. PubMed ID: 17374234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
